Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Forest Laboratories LLC
Current Parent Company: AbbVie
Penalty: $27,200,000
Year: 2023
Date: March 23, 2023
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Forest Laboratories and Merz Pharmaceuticals together agreed to pay over $54 million to indirect purchaser plaintiffs to settle litigation alleging they were part of a pay-for-delay scheme to block the introduction of a lower-cost generic version of the Alzheimer's drug Namenda. Court documents did not indicate how much each would pay. Here we assume they divided the total equally between them.
Level of Government: federal
Action Type: private litigation
Court: Southern District of New York
Civil or Criminal Case: civil
Case ID: 1:15cv6549
Case Name: In re Namenda Indirect Purchaser Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: Illinois
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.